dctd-nanopi (Agenda)

2022 NCI ALLIANCE FOR NANOTECHNOLOGY IN CANCER

PRINCIPAL INVESTIGATOR MEETING
October 18-19, 2022 Virtual Meeting

 

DAY 1: October 18, 2022

9:00 am – 10:00 am

Join Meeting – Computer Check

10:00 am – 10:20 am

Welcome and Introduction
Janet Eary, M.D., Associate Director, CANCER IMAGING PROGRAM (CIP), DCTD, NCI
Piotr Grodzinski, Ph.D., Branch Chief, NSDB, CIP, DCTD, NCI

10:20 am – 11:00 am

Plenary presentation
Molly S Shoichet, Ph.D., UNIVERSITY OF TORONTO

SESSION I: CANCER INTERVENTIONS ENABLED BY NEW MATERIAL DESIGNS (PART 1)
MODERATOR: Piotr Grodzinski , Ph.D., Branch Chief, NSDB, CIP, DCTD, NCI
11:00 am – 11:20 am

The tumor microenvironment in nanoparticle delivery and function
Zaver, Bhujwalla, Ph.D., JOHNS HOPKINS UNIVERSITY

11:20 am – 11:40 am

Imaging of nanotherapeutic drug action
Presented by Miles Miller, Ph.D., MASSACHUSETTS GENERAL HOSPITAL
(PI Ralph Weissleder, M.D., Ph.D., MASSACHUSETTS GENERAL HOSPITAL)

11:40 am – 12:00 pm

Copper-depleting nanotheranostics for treating triple negative breast cancer
Jianghong Rao, Ph.D., STANFORD UNIVERSITY

12:00 pm – 12:20 pm

In situ cancer cell specific biomineralization to overcome nanoparticle delivery barriers and sensitize pancreatic cancer to radiotherapy
Konstantin Sokolov, Ph.D., UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

12:20 pm – 12:40 pm

Fluorescent indocarbocyanine PEGylated lipid nanoparticles for understanding and
overcoming barriers to drug delivery in invasive glioblastoma

Dmitri Simberg, Ph.D., UNIVERSITY OF COLORADO DENVER

12:40 pm – 1:10 pm

LUNCH BREAK

Session II. Discussion Panel: WHAT WILL BE THE NEXT NANO-DRUG APPROVED BY FDA?
Moderator: Andrew Wang, M.D., UT SOUTHWESTERN MEDICAL CENTER
1:10 pm – 2:10 pm

Panel:

  1. Andre Nel, M.D., Ph.D., UNIVERSITY OF CALIFORNIA, LOS ANGELES
  2. Aleks Radovic-Moreno, Ph.D., LONGWOOD FUND
  3. Stephan Stern, Ph.D., DABT, NANOTECHNOLOGY CHARACTERIZATION LABORATORY
SESSION III: NOVEL CANCER THERAPIES BASED ON NANOTECHNOLOGY
MODERATOR: Carolina Salvador Morales, Ph.D., Program Director, NSDB, CIP, DCTD, NCI
2:10 pm - 2:30 pm

Ultrasmall particle-based solutions for inducing ferroptosis and improving antitumor immune responses in cancer
Michelle Bradbury, M.D., Ph.D., MEMORIAL SLOAN KETTERING CANCER CENTER

2:30 pm - 2:50 pm

Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis
Lily Yang, M.D., Ph.D., EMORY UNIVERSITY

2:50 pm - 3:10 pm

Nanodelivery platform for antibody drugs targeting NHL
Masakazu Kamata, Ph.D., UNIVERSITY OF ALABAMA AT BIRMINGHAM

3:10 pm - 3:30 pm

Towards translation of MU-CN29: New therapeutic nanoparticle for drug resistant NSCLC
Raghuramann Kannan, M.D., UNIVERSITY OF MISSOURI-COLUMBIA

3:30 pm – 3:45 pm

BREAK

3:45 pm - 4:05 pm

Targeted therapeutics for ovarian cancer and its microenvironment - treatment and theoretical modeling
Gabriel Lopez-Berestein, M.D., UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

4:05 pm - 4:25 pm

TNBC ligand-displaying exosomes using RNA nanotechnology for targeted cytosol delivery of RNAi without endosome entrapment
Presented by Daniel Binzel, Ph.D., OHIO STATE UNIVERSITY (MPI)
(PI Dan Shu, M.D., OHIO STATE UNIVERSITY)

4:25 pm - 4:45 pm

Novel approach to attenuate small cell lung cancer growth and metastasis
Mohd Wasim Nasser, Ph.D., UNIVERSITY OF NEBRASKA MEDICAL CENTER

4:45 pm - 5:00 pm

Q&A/Day 1 Wrap-up
Carolina Salvador Morales, Ph.D., Program Director, NSDB, CIP, DCTD, NCI

DAY 2: October 19, 2022

9:00 am - 10:00 am

Join Meeting-Computer Check

10:00 am - 10:10 am

Day 1 recap

SESSION IV: CANCER INTERVENTIONS ENABLED BY NEW MATERIAL DESIGNS (PART 2)
MODERATOR: Carolina Salvador Morales, Ph.D., Program Director, NSDB, CIP, DCTD, NCI
10:10 am - 10:30 am

Development of a novel biodegradable inorganic nanoparticle therapeutic for cancer
Jin Xie, Ph.D., UNIVERSITY OF GEORGIA

10:30 am - 10:50 am

The development of novel radiation-sensitizer based on ultra-small carbon dots
Zibo Li , Ph.D., UNIVERSITY OF NORTH CAROLINA, CHAPEL HILL

10:50 am - 11:10 am

Stimuli-responsive mucin1-specific nanoparticles for efficacious combinatorial
chemotherapy of pancreatic ductal adenocarcinoma

Juan Luis Vivero-Escoto, Ph.D., UNIVERSITY OF NORTH CAROLINA, CHARLOTTE

11:10 am - 11:30 am

Nanotechnology for targeted therapy and fundamental understanding of
therapeutic resistance in triple negative breast cancer

Xiaoming He, Ph.D., UNIVERSITY OF MARYLAND, COLLEGE PARK

11:30 am - 11:50 am

Map leukemia-immune cell talks with nanoplasmon ruler in CAR T-cell immunotherapy
Presented by Pengyu Chen, Ph.D., AUBURN UNIVERSITY (MPI)
(PI Weiqiang Chen, Ph.D., NEW YORK UNIVERSITY)

11:50 am - 12:20 pm

LUNCH BREAK

SESSION V: PANEL DISCUSSION: CAN NANOTECHNOLOGY AID IN COMBATING CANCER METASTASIS?
Moderator: Patricia Steeg, Ph.D., CENTER FOR CANCER RESEARCH, NCI
12:20 pm - 1:20 pm

PANEL:

  1. Hannah Linden, M.D., F.A.C.P, FRED HUTCHINSON CANCER RESEARCH CENTER
  2. Wasim Nasser, Ph.D., UNIVERSITY OF NEBRASKA MEDICAL CENTER
  3. Baran Sumer, M.D., F.A.C.S., UT SOUTHWESTERN MEDICAL CENTER
SESSION VI: IMMUNOTHERAPIES AND VACCINES
MODERATOR: Leela Rani Avula, Ph.D., Program Director, NSDB, CIP, DCTD, NCI
1:20 pm – 1:40 pm

A cobalt porphyrin nanoliposome adjuvant for MHC-I-restricted cancer peptide vaccines
Jonathan Lovell, Ph.D., STATE UNIVERSITY OF NEW YORK AT BUFFALO

1:40 pm – 2:00 pm

Innovative research for cancer nanotechnology (IRCN) for enhancing melanoma-
specific immune responses by the rational design of spherical nucleic acids

Presented by Bin Zhang, M.D., Ph.D., NORTHWESTERN UNIVERSITY (MPI)
(PI Chad Mirkin, Ph.D., NORTHWESTERN UNIVERSITY)

2:00 pm – 2:20 pm

Targeting effector immune cells to cancer with chemically self-assembled nanorings (CSANs)
Carston Wagner, Ph.D., UNIVERSITY OF MINNESOTA

2:20 pm - 2:40 pm

BREAK

2:40 pm – 3:00 pm

Toward translation of an immunotherapeutic nanomedicine for neuroblastoma
John Tanner Wilson, Ph.D., VANDERBILT UNIVERSITY

3:00 pm – 3:20 pm

Whitlockite nanoparticle-based immunotherapy for bone metastasis
Presented by Hae Lin Jang, Ph.D., BRIGHAM AND WOMEN'S HOSPITAL (MPI)
(PI Shiladitya Sengupta, Ph.D., BRIGHAM AND WOMEN'S HOSPITAL)

3:20 pm – 3:40 pm

Toward translation of a plant virus-based in situ vaccination nanotechnology
Nicole Franziska Steinmetz, Ph.D., UNIVERSITY OF CALIFORNIA, SAN DIEGO

3:40 pm- 4:00 pm

Closing Remarks
Piotr Grodzinski, Ph.D., Branch Chief, NSDB, CIP, DCTD, NCI